{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-043166","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2025-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.869170+00:00","generated_at":"2026-05-24T08:57:53.214422+00:00","sec_items":["1.01","2.02","7.01","3.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tivic Health FY2024 net loss narrows to $5.7M; secures $25M equity line, in-licenses Entolimod","bullets":["FY2024 revenue $0.8M (down from $1.2M); net loss -$5.7M vs -$8.2M in 2023 (30% decrease).","Entered $25M equity purchase agreement with Mast Hill Fund; issued 29,800 commitment shares.","In-licensed late-stage TLR5 agonist Entolimod from Statera Biopharma for acute radiation syndrome (Phase III).","Appointed Michael Handley as COO and President of Tivic Biopharma; Lisa Wolf as interim CFO.","ncVNS optimization study completed enrollment; disease-specific trials planned in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-043166","json":"https://secwatch.observer/filing/0000950170-25-043166.json","markdown":"https://secwatch.observer/filing/0000950170-25-043166.md","text":"https://secwatch.observer/filing/0000950170-25-043166.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025043166/0000950170-25-043166-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025043166/tivc-20250318.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T08:57:53.214422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}